drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cell)
drug_description
Autologous, fully human anti-BCMA chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are engineered to express a CAR that binds BCMA; antigen engagement triggers CAR signaling leading to T-cell expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity against BCMA-positive malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a fully human anti-BCMA chimeric antigen receptor. Upon binding BCMA on malignant plasma cells, CAR signaling activates and expands the T cells, inducing cytokine release and perforin/granzyme-mediated cytotoxicity to eliminate BCMA-positive multiple myeloma cells.
drug_name
Zevorcabtagene autoleucel (zevor-cel)
nct_id_drug_ref
NCT06659770